Aardvark Therapeutics' ARD-101 Path Forward May Be Challenging, RBC Says

MT Newswires Live09-24 23:20

Aardvark Therapeutics (AARD) faces a "potentially challenging" path forward for ARD-101 in Prader-Willi syndrome, with unblinded data from a halted phase 3 study expected to provide additional insight, RBC Capital Markets said in a note Thursday.

The phase 3 study was previously halted by the US Food and Drug Administration due to cardiac signals, prompting unblinding of the study, the analysts said.

RBC expects the resulting dataset to include patients treated for varying durations, including a limited number who completed the study.

The dataset's interpretability could be limited by the short treatment duration and differences in exposure, particularly because the study used higher doses after an initial 200mg period, according to the note.

Clear reductions in hunger scores among patients receiving ARD-101 compared with placebo could provide more "definitive support", RBC said.

RBC maintained its sector perform rating and $6 price target on Aardvark Therapeutics.

Price: 5.53, Change: -0.03, Percent Change: -0.54

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment